bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement Read more about bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results Read more about bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results
bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program Read more about bluebird bio to Present Updated Results From Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma During ASCO20 Virtual Scientific Program
BofA Securities Health Care Conference 2020 Read more about BofA Securities Health Care Conference 2020
bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event Read more about bluebird bio Announces First Quarter 2020 Earnings Conference Call and May Investor Event
Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA Read more about Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA
bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development Read more about bluebird bio Provides Assessment of Impact of COVID-19, Update on Business Operations and Clinical Program Development
bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress
bluebird bio Announces Upcoming Investor Events Read more about bluebird bio Announces Upcoming Investor Events
bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β⁰/β0 Genotype Read more about bluebird bio Announces Launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β⁰/β0 Genotype